PUBBLICAZIONI SCIENTIFICHE
I risultati delle ricerche finanziate dalla Associazione in questi anni sono stati presentati
in numerosi convegni e congressi nazionali ed internazionali e pubblicati su importanti riviste scientifiche.
IMPACT FACTOR
L'impact factor dei lavori scientifici è attualmente di 2143,60 punti considerando l'I.F. più recente della rivista
- Pubblicazione:
- Hematological Oncology 40-5:953-961, 2022 - I.F. 4,85
141 – Characteristics and clinical outcomes of patients with ALK- Positive anaplastic large cell lymphoma: report from the Prospective International T-Cell Lymphoma Project
- AUTORI: Chiattone C., Civallero M., Fischer T., Miranda M., Zing N.P.C., Pileri S.A., Montoto S., Horwitz S.M., Cabrera M.E., De Souza C.A., Nagler A., Luminari S., Ferreri A.J.M., Carson K.R., Re A., Rigacci L., Nassi L., Stepanishyna Y., Federico M., Inghiran
Abstract The T-cell Lymphoma Project is an international registry prospective study that enrolled patients with newly diagnosed peripheral T-cell and NK-cell lymphomas (PTCL). The
- Pubblicazione:
- Hematological Oncology, 2022 - I.F. 5,27
140 – Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification
- AUTORI: Kriachok I., Stepanishyna Y., Skrypets T., Shokun N., Martvnchyk A., Tytoremko I., Aleksik O., Krotevych M., Manni M., Federico M.:
Abstract The Ukrainian Lymphoma Registry (ULR) was established in 2019 with the aim of monitoring the quality of diagnosis, staging, and treatment of lymphoma
- Pubblicazione:
- Cancer, 2021 - I.F. 5,73
139 – Insights into the possible molecular mechanisms of resistance to PARP inhibitors
- AUTORI: Piombino C., Cortesi L.
Abstract PARP1 enzyme plays an important role in DNA damage recognition and signalling. PARP inhibitors are approved in breast, ovarian, pancreatic, and prostate cancers
- Pubblicazione:
- Frontieres in Oncology-Breast Cancer, 2021 - I.F. 5,73
- AUTORI: Cortesi L., Galli G.R., Domati F., Conte L., Manca L., Berio M.A., Toss A., Iannone A., Federico M.
Abstract Background: Adult body fatness is a convincing risk factor for postmenopausal breast cancer. With the aim to compare the different breast cancer (BC)
- Pubblicazione:
- Journal of Clinical Oncology 40-7:729-739, 2021 - I.F. 44,54
- AUTORI: Luminari S., Manni M., Galimberti S., Versari A., Tucci A., Boccomini C., Farina L., Olivieri J., Marcheselli L., Guerra L., Ferrero S., Arcaini L., Cavallo F., Kovalchuk S., Skrypets T., Del Giudice I., Chauvie S., Patti C., Stelitano C., Ricci F., Pinto
Abstract Purpose: We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction
- Pubblicazione:
- Journal of Perzonalized Medicine 11:6-580, 2021 - I.F. 4,94
- AUTORI: Toss.A., Spinella A., Isca C., Vacchi C., Ficarra G., Fabbiani L., Iannone A. et al.
Abstract: The most common breast cancer (BC) susceptibility genes beyond BRCA1/2 are ATM and CHEK2. For the purpose of exploring the clinicopathologic characteristics of
- Pubblicazione:
- Blood Advances 5:3-640:648, 2021 - I.F.6,68
- AUTORI: Shoustov A., Cabrera M.E., Civallero M., Bellei M., Ko Y.H., Manni M., Skrypets T. et al.
Abstract: The most common breast cancer (BC) susceptibility genes beyond BRCA1/2 are ATM and CHEK2. For the purpose of exploring the clinicopathologic characteristics of
- Pubblicazione:
- Genes 12:5-616, 2021 - I.F. 3,75
- AUTORI: Toss A., Tenedini E., Piombino C., Venturelli M., Marchi I., Gasparini E., Barbieri E. et al.
Abstract: The most common breast cancer (BC) susceptibility genes beyond BRCA1/2 are ATM and CHEK2. For the purpose of exploring the clinicopathologic characteristics of
- Pubblicazione:
- Biomedicines 9:3-312, 2021 - I.F. 4,71
- AUTORI: Piombino C., Mastrolia I., Omarini C., Candini O., Dominici M., Piacentini F., Toss A.
Abstract: The importance of molecular re-characterization of metastatic disease with the purpose of monitoring tumor evolution has been acknowledged in numerous clinical guidelines for
- Pubblicazione:
- Diagnostic 11:3-565, 2021 - I.F. 5,25
- AUTORI: Toss A., Piombino C., Tenedini E., Bologna A., Gasparini E., Tarantino V., Filieri ME. et al.
Abstract: Previous research involving epithelial ovarian cancer patients showed that, compared to germline BRCA (gBRCA) mutations, somatic BRCA (sBRCA) mutations present a similar positive
- Pubblicazione:
- Journal of Personalized Medicine, 11:4-245, 2021 - I.F. 4,90
- AUTORI: Cortesi L., Domati F., Guida A., Marchi I., Toss A., Barbieri E. et al.
Abstract: The homologous recombination repair (HRR) pathway repairs double-strand DNA breaks, mostly by BRCA1 and BRCA2, although other proteins such as ATM, CHEK2, and
- Pubblicazione:
- Cancer Biology and Medicine, 18:2-470:476, 2021 - I.F. 5,43
- AUTORI: Cortesi L., Domati F., Guida A., Marchi I., Toss A., Barbieri E., Marcheselli L. et al.
Objective: As prostate cancer (PrC) shows a BRCA mutation rate as high as 30%, it becomes crucial to find the optimal selection criteria for
- Pubblicazione:
- Journal of Oncology, 2020 - I.F. 4,37
- AUTORI: Piombino C., Cortesi L., Lambertini M., Punie K., Grandi G., Toss A.
BRCA1- and BRCA2-associated hereditary breast and ovarian cancer syndromes are among the best-known and most extensively studied hereditary cancer syndromes. Nevertheless, many patients who
- Pubblicazione:
- ESMO Open 6:2, 2021 - I.F. 4,93
- AUTORI: Toss A., Isca C., Venturelli M., Nasso C., Ficarra G., Bellelli V., Armocida C. et al.
Introduction: The present analysis aims to evaluate the consequences of a 2-month interruption of mammographic screening on breast cancer (BC) stage at diagnosis and
- Pubblicazione:
- British Journal of Haematology 192:6-1011:1014, 2021 - I.F. 5,02
- AUTORI: Massaro F., Stepanishyna Y., Manni M., Luminari S., Galimberti S., Marcheselli L., Visco C. et al.
Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the MCL01 trial, patients were treated with the R-HCVAD regimen [rituximab plus HyperCVAD
- Pubblicazione:
- Cancers 12:7-1709, 2020 - I.F. 6,12
- AUTORI: Cortesi L., Sebastiani F., Iannone A., Marcheselli L., Venturelli M., Piombino C., Toss A., Federico M.
Background obesity and sedentary lifestyle have been shown to negatively affect survival in breast cancer (BC). The purpose of this study was to test
- Pubblicazione:
- Cancers 12:5-1252, 2020 - I.F. 6,12
- AUTORI: Toss A., Molinaro E., Venturelli M., Domati F., Marcheselli L., Piana S. et al.
NCCN Guidelines recommend BRCA genetic testing in individuals with a probability >5% of being a carrier. Nonetheless, the cost-effectiveness of testing individuals with no
- Pubblicazione:
- Apoptosis 5:6-370:387, 2020 - I.F. 4,02
- AUTORI: Cosenza M., Civallero M., Marcheselli L., Sacchi S., Pozzi S.
Histone deacetylase (HDAC) inhibitors represent an encouraging class of antitumor drugs. HDAC inhibitors induce a series of molecular and biological responses and minimal toxicity
- Pubblicazione:
- Lancet Haematology 7:4-e284:e294, 2020 - I.F. 11,90
- AUTORI: Fox CP., Civallero M., Ko YH., Manni M., Skrypets T., Pileri S., Kim SJ. et al.
Background Extranodal natural killer (NK) T-cell lymphoma (ENKTL) is a unique clinicopathological entity, typically associated with poor survival outcomes. Most published data have come
- Pubblicazione:
- International Journal of Molecular Sciences 19:8-2337, 2018 - I.F. 4,55
- AUTORI: Cosenza M., Pozzi S.
Histone deacetylases (HDACs) are master regulators of chromatin remodeling, acting as epigenetic regulators of gene expression. In the last decade, inhibition of HDACs has
- Pubblicazione:
- Journal of Clinical Oncology 36:7-689:696, 2018 - I.F. 28,24
- AUTORI: Luminari S., Ferrari A., Manni M., Dondi A., Chiarenza A., Merli F. et al.
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab
- Pubblicazione:
- Cancers 11:2-193:204, 2019 - I.F. 6,12
- AUTORI: Toss A., Venturelli M., Molinaro E., Pipitone S., Barbieri E., Marchi I., Tenedini E., Artuso L., Castellano S., Marino M., Tagliafico E., Razzaboni E., De Matteis E., Cascinu S., Cortesi L.
The identification of BRCA mutations plays a crucial role in the management of hereditary cancer prevention and treatment. Nonetheless, BRCA-testing in pancreatic cancer (PC)
- Pubblicazione:
- Frontiers in Oncology 8-254, 29 - I.F. 4,41
- AUTORI: Gibellini L., Losi L., De Biasi S., Nasi M., Lo Tartaro D. et al
Mitochondrial Lon protease (LonP1) is a multi-function enzyme that regulates mitochondrial functions in several human malignancies, including colorectal cancer (CRC). The mechanism(s) by which
- Pubblicazione:
- Blood 131:13-1456:1463, 2018 - I.F. 22,11
- AUTORI: Cottereau AS., Versari A., Loft A., Casanovas O., Bellei M., Ricci R. et al
We tested baseline positron emission tomography (PET)/computed tomography (CT) as a measure of total tumor burden to better identify high-risk patients with early-stage Hodgkin
- Pubblicazione:
- British Journal of Haematology 181:6-760:769, 2019 - I.F. 6,99
- AUTORI: Federico M., Bellei M., Marcheselli L., Schwartz M., Manni M., Tarantino V. et al
Different models to investigate the prognosis of peripheral T cell lymphoma not otherwise specified (PTCL-NOS) have been developed by means of retrospective analyses. Here
- Pubblicazione:
- Haematologica 103:7-1191:1197, 2018 - I.F. 9,94
- AUTORI: Bellei M., Foss FM., Shustov A., Horwitz SM., Marcheselli L., Federico M. et al
This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell project. We
- Pubblicazione:
- Oncotarget 8:61-103797:103814, 2017 - I.F. 3,33
- AUTORI: Civallero M., Cosenza M., Pozzi S., Sacchi S.
JAK-2 dysregulation plays an important role as an oncogenic driver, and is thus a promising therapeutic target in hematological malignancies. Ruxolitinib is a pyrrolo[2.3-d]pyrimidine
- Pubblicazione:
- Oncology 93:6-377:386, 2017 - I.F. 2,93
- AUTORI: Cortesi L., De Matteis E., Toss A., Marchi I., Medici V., Contu G. et al.
Objective: To evaluate the effectiveness of transvaginal ultrasound (TVU) and serum CA-125 measurement in women at different risk of developing ovarian cancer/fallopian tube cancer
- Pubblicazione:
- Apoptosis 22:6-827:840, 2017 - I.F. 4,67
- AUTORI: Cosenza M., Civallero M., Marcheselli L., Sacchi S., Pozzi S.
Histone deacetylase inhibitors (HDACis) have emerged as a new class of anticancer agents, targeting the biological process including cell cycle and apoptosis. We investigated
- Pubblicazione:
- Journal of Clinical Oncology 35:16-1786:1794, 2017 - I.F. 44,54
- AUTORI: Andrè MP., Girinsky TR., Federico M., Reman O., Fortpied C. et al.
Purpose Patients who receive combined modality treatment for stage I and II Hodgkin lymphoma (HL) have an excellent outcome. Early response evaluation with positron
- Pubblicazione:
- Hematological Oncology 35:4-630:636, 2016 - I.F. 5,27
- AUTORI: Bellei M., Sabattini E., Pesce EA., Ko YH., Kim WS., Cabreras ME. et al.
Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post-thymic lymphoid cells at different stages of differentiation with different
- Pubblicazione:
- Blood 127:12-1531:1534, 2016 - I.F. 22,11
- AUTORI: Barrington SF., Kirkwood AA., Franceschetto A., Fulham MJ., Roberts TH., Almquist H. et al.
International guidelines recommend that positron emission tomography-computed tomography (PET-CT) should replace CT in Hodgkin lymphoma (HL). The aims of this study were to compare
- Pubblicazione:
- BioMed Research International 1:12, 2015 - I.F. 3,41
- AUTORI: Civallero M., Cosenza M., Pozzi S., Bari A., Ferri P., Sacchi S.
Non-Hodgkin lymphomas encompass a heterogeneous group of cancers, with 85–90% arising from B lymphocytes and the remainder deriving from T lymphocytes or NK lymphocytes.
- Pubblicazione:
- Mayo Clinic Proceedings 90:6-756-764, 2015 - I.F. 7,61
- AUTORI: Tadmor T., Bari A., Marcheselli L., Sacchi S., Aviv A., Baldini L. et al.
OBJECTIVE: To verify whether absolute monocyte count (AMC) and lymphocyte- monocyte ratio (LMR) at diagnosis are valid prognostic parameters in classical Hodgkin lymphoma (cHL).
- Pubblicazione:
- British Journal of Haematololy 169:4-544:551, 2015 - I.F. 6,99
- AUTORI: Marcheselli L., Bari A., Anastasia A., Botto B., Puccini B. et al.
Recently, in an attempt to improve the discrimination power of the international prognostic index (IPI), patients with diffuse large B-cell lymphoma were evaluated to
- Pubblicazione:
- Annals of Epidemiology 25:8-564:568, 2015 - I.F. 3,79
- AUTORI: El Mistiri M., Salati M., Marcheselli L., Attia A., Habil S. et al.
Purpose: Despite the increasing burden of cancer occurred over recent years in the African continent, epidemiologic data from Northern Africa area have been so
- Pubblicazione:
- International Journal of Cancer 137:6-1417:1426, 2015 - I.F. 7,39
- AUTORI: Cortesi L., Toss A., Cirilli C., Marcheselli L., Braghiroli B., Sebastiani F., Federico M.
Although new treatments have been widely studied to improve the survival of patients with metastatic breast cancer (BC), prognosis continues to be poor with
- Pubblicazione:
- Hematological Oncology 33:4-166:175, 2015 - I.F. 5,27
- AUTORI: Cosenza M., Civallero M., Pozzi S., Marcheselli L., Bari A., Sacchi S.
We analyzed the combination of a proteasome inhibitor (bortezomib) with enzastaurin (PKC/AKT-inhibitor) or lenalidomide (immunomodulatory agent) for the inhibition of proliferation and induction of
- Pubblicazione:
- Britisch JOurnal of Haematology 165:6-892, 2014 - I.F. 6,99
- AUTORI: Pozzi S., Bari A., Sacchi S.
The study by Murphy et al supports the observation made by several groups regarding the benefit of the novel agents in both young and
- Pubblicazione:
- Expert Opinion Investig Drugs 23:5-711:718, 2014 - I.F. 6,20
- AUTORI: Dondi A., Bari A., Pozzi S., Ferri P., Sacchi S.
Introduction: Peripheral T-cell lymphomas (PTCLs) are a group of rare malignancies originating from clonal proliferation of mature, post-thymic T cells that represent 10 —
- Pubblicazione:
- Journal Clinical of Oncology 32:12-1188:1194, 2014 - I.F. 44,54
- AUTORI: Raemaekers JM., André MP., Federico M., Girinsky T., Oumedaly R., Brusamolino E., Brice P. et al.
Purpose Combined-modality treatment is standard treatment for patients with clinical stage I/II Hodgkin lymphoma (HL). We hypothesized that an early positron emission tomography (PET)
- Pubblicazione:
- Hematological Oncology 33:3-147:151 2014 - I.F. 5,27
- AUTORI: Biasoli I., Cesaretti M., Bellei M., Maiorana A., Bonacorsi G., Quaresima M. et al. et al.
We conducted a population-based study to establish the outcome of T-cell lymphoma (TCL) patients failing systemic first-line therapy. All TCL patients failing first-line systemic
- Pubblicazione:
- Annals of Oncology 25-442:447, 2014 - I.F. 32,97
- AUTORI: Luminari S., Biasoli I., Versari A., Rattotti S., Bottelli C., Rusconi C., Merli F., Spina M., Ferreri A.J.M., Zinzani P.L. et al.
Background: [ 18F]fluorodeoxyglucose-positron emission tomography (PET) is emerging as a strong diagnostic and prognostic tool in follicular lymphoma (FL) patients. Patients and methods: In
- Pubblicazione:
- Haematologica 99:1-125:130, 2014 - I.F. 9,54
- AUTORI: Tadmor T., Bari A., Sacchi S., Marcheselli L., Liardo EV., Avivi I., Beniamini N. et al.
In this study we assessed the prognostic significance of absolute monocyte count and elected the best cut-off value at diagnosis, in a large cohort
- Pubblicazione:
- Annals of Oncology 25-57:63, 2014 - I.F. 32,97
- AUTORI: Cortesi L., Razzaboni E., Toss A., De Matteis E., Marchi I., Medici V., Tazzioli G., Andreotti A., De Santis G., Pignatti M., Federico M.
Background: Risk-reducing mastectomy (RRM) decreases breast cancer (BC) risk in BRCA1/2 mutation carriers by up to 95%, but the Italian attitude towards this procedure
- Pubblicazione:
- Professioni Infermieristiche 67:1-55:56, 2014
- AUTORI: Magnani D., Di Lorenzo R., Bari A., Pozzi S., Del Giovane C., Ferri P.
Background: Nursing students have to deal with many different clinical and practical aspects of knowledge to become skilled professionals. Student perception may be considered
- Pubblicazione:
- Blood 122:23-3759:3766, 2013 - I.F. 22,11
- AUTORI: Ladetto M , Lobetti-Bodoni C , Mantoan B , Ceccarelli M , Boccomini C , Bari A et al.
We assessed the prognostic value of minimal residual disease (MRD) within the ML17638 phase 3 trial from the Fondazione Italiana Linfomi, investigating the role
- Pubblicazione:
- British Journal of Haematology 163:1-40:46, 2013 - I.F. 6,99
- AUTORI: Pozzi S., Marcheselli L., Bari A., Liardo EV., Marcheselli R. et al.
Novel treatments for multiple myeloma (MM) have shown promising results in clinical trials, but the advantage in unselected patients is still unclear. In order
- Pubblicazione:
- Journal Clinical of Oncology 31:27-3351:3359, 2013 - I.F. 44,54
- AUTORI: Vitolo U., Ladetto M., Boccomini C., Baldini L., De Angelis F., Bari A. et al.
Purpose To evaluate the efficacy of rituximab maintenance in 60- to 75-year-old patients with advanced follicular lymphoma responding to brief first-line chemoimmunotherapy followed by
- Pubblicazione:
- Leukemia Research 37:6-619:623, 2013 - I.F. 3,15
- AUTORI: Bari A., Tadmor T., Sacchi S., Marcheselli L. et al.
In this retrospective study we evaluated the prognostic impact of peripheral blood monocytosis in patients with T-cell non Hodgkin lymphomas with “aggressive-typically nodal presentation”.
RICERCA SUL CANCRO
PUBBLICAZIONI SCIENTIFICHE
Tutti i nostri articoli pubblicati sulle riviste scientifiche
VAI
PROGETTI DI RICERCA
I progetti di ricerca che abbiamo sostenuto
VAI
BORSE DI STUDIO E STAGE ALL'ESTERO
Borse di studio e stage all'estero per ricercatori finanziati dall'Associazione
VAI
PREMI DI STUDIO
Stage all'estero per ricercatori sostenuti dall'Associazione
VAI
PREMIO "PIER CAMILLO BECCARIA"
Conferito ogni anno ad un illustre studioso che si è distinto nella lotta contro i tumori
VAI